- Home
- LEGN vs CORT Comparison
LEGN vs CORT Comparison
Compare LEGN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- CORT
- Stock Information
- Founded
- LEGN 2014
- CORT 1998
- Country
- LEGN United States
- CORT United States
- Employees
- LEGN N/A
- CORT N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- LEGN Health Care
- CORT Health Care
- Exchange
- LEGN Nasdaq
- CORT Nasdaq
- Market Cap
- LEGN 5.4B
- CORT 7.5B
- IPO Year
- LEGN 2020
- CORT N/A
- Fundamental
- Price
- LEGN $35.91
- CORT $71.34
- Analyst Decision
- LEGN Strong Buy
- CORT Strong Buy
- Analyst Count
- LEGN 13
- CORT 4
- Target Price
- LEGN $75.17
- CORT $142.00
- AVG Volume (30 Days)
- LEGN 2.1M
- CORT 1.6M
- Earning Date
- LEGN 08-08-2025
- CORT 07-28-2025
- Dividend Yield
- LEGN N/A
- CORT N/A
- EPS Growth
- LEGN N/A
- CORT 8.36
- EPS
- LEGN N/A
- CORT 1.14
- Revenue
- LEGN $728,303,000.00
- CORT $685,446,000.00
- Revenue This Year
- LEGN $65.49
- CORT $35.83
- Revenue Next Year
- LEGN $53.76
- CORT $35.24
- P/E Ratio
- LEGN N/A
- CORT $62.45
- Revenue Growth
- LEGN 112.46
- CORT 30.93
- 52 Week Low
- LEGN $27.34
- CORT $29.42
- 52 Week High
- LEGN $60.87
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- LEGN 59.23
- CORT 47.36
- Support Level
- LEGN $32.42
- CORT $72.48
- Resistance Level
- LEGN $36.91
- CORT $75.95
- Average True Range (ATR)
- LEGN 1.54
- CORT 2.74
- MACD
- LEGN 0.04
- CORT -0.16
- Stochastic Oscillator
- LEGN 50.29
- CORT 31.69
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.